General
Preferred name
RABEPRAZOLE
Synonyms
RABEPRAZOLE SODIUM ()
LY307640 sodium ()
LY307640 ()
Rebeprazole sodium ()
Habeprazole Sodium ()
Dexrabeprazole Sodium ()
Aciphex Sodium ()
Rabeprazole Sodium salt ()
Aciphex / Pariet ()
RABEPRAZOLE117976-89-3 ()
Rabeprazole (sodium) ()
LY307640 (sodium) ()
Aciphex Sodium, Dexrabeprazole Sodium, Habeprazole Sodium ()
Rabeprazole (sodium salt) ()
Aciphex sprinkle ()
Pariet ()
E-3810 ()
Sodium rabeprazole ()
LY-307640 SODIUM ()
NSC-759270 ()
Rabeprazole sodium salt ()
LY307640 SODIUM ()
Aciphex ()
Idiazole ()
Rabeprazole na ()
E-3810 SODIUM ()
LY-307640 ()
E-3810 (PPI) ()
Rabeprazol ()
E3810 ()
Pariprazole ()
Eraloc ()
Rabeprazole-d4 (sodium salt) ()
P&D ID
PD002894
CAS
117976-90-6
117976-89-3
Tags
available
drug
Approved by
FDA
First approval
1999
Drug indication
Gastroesophageal reflux disease
Bacterial infection
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 ¦ÌM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux[1][2][3].
PRICE 30
DESCRIPTION Rabeprazole is a proton pump inhibitor. This compound is a prodrug which is converted into the active sulphenamide form in the acid environment of the parietal cells.
Marketed formulations may contain rabeprazole sodium (PubChem CID 14720269). (GtoPdb)
DESCRIPTION Rabeprazole (LY307640) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 ¦ÌM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux[1][2][3].
PRICE 38
DESCRIPTION Rabeprazole sodium (Habeprazole Sodium) is a 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of stomach ulcers and Zollinger-Ellison syndrome. The drug inhibits H(+)-K(+)-exchanging ATPase which is found in gastric parietal cells. (TargetMol Bioactive Compound Library)
DESCRIPTION Rabeprazole (LY307640) is an H+/K+-ATPase inhibitor that inhibits cell proliferation in gastric epithelial cells by targeting STAT3-mediated glycolysis and can be used in the study of gastric ulcers. (TargetMol Bioactive Compound Library)
Cell lines
2
Organisms
4
Compound Sets
25
Cayman Chemical Bioactives
14939
26118
ChEMBL Approved Drugs
CHEMBL1200930
CHEMBL1219
ChEMBL Drugs
CHEMBL1200930
CHEMBL1219
DrugBank
DB01129
DrugBank Approved Drugs
DB01129
DrugCentral
2350
DrugCentral Approved Drugs
2350
DrugMAP
DMMZXIW
DrugMAP Approved Drugs
DMMZXIW
DrugMatrix
Guide to Pharmacology
7290
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1219
Mcule NIBR MoA Box Subset
MCULE-7848941080
MedChem Express Bioactive Compound Library
HY-B0656A
HY-B0656
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
32828355LL
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Other bioactive compounds
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
rabeprazole-sodium
rabeprazole
TargetMol Bioactive Compound Library
T1651
T19826
The Spectrum Collection
External IDs
76
Properties
(calculated by RDKit )
Molecular Weight
359.13
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
1
Rotatable Bonds
8
Ring Count
3
Aromatic Ring Count
3
cLogP
2.99
TPSA
77.1
Fraction CSP3
0.33
Chiral centers
1.0
Largest ring
6.0
QED
0.63
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Potassium Channel
STAT3
Apoptosis
Proton Pump
Bacterial
Member status
virtual
MOA
H+/K+-ATPase Inhibitors
Therapeutic Indication
Antiulcer
Pathway
JAK/STAT Signaling
Membrane Transporter/Ion Channel
Stem Cells
Anti-infection
Therapeutic Class
Antiulcer Agents
Source data